Extended indication In combination with bortezomib, lenalidomide and dexamethasone (Isa VRd) in patients with newly diag
Therapeutic value No estimate possible yet
Total cost 24,542,073.00
Registration phase Registration application pending

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information